PLGA, Poly (L-lactide-co-glycolide)
The peptide's demonstrated safety in gastric juice stability and lack of toxic effects across wide dose ranges support its potential for gastrointestinal therapeutic applications pending further clinical validation

Possible clinical applications for elevated glutathione levels Neurology Parkinsons disease Alzheimers disease Seizures Multiple sclerosis Eye diseases Cataracts Macular degeneration Glaucoma Cardiovascular Prevent heart disease Prevent stroke Prevent atherosclerosis Prevent reperfusion injury Digestive system Inflammatory bowel disease Hepatitis Malnutrition Pancreatitis Peptic Ulcer Toxicology Certain drug overdoses Tobacco smoke, auto exhaust Pollutants including heavy metals, pesticides Prevents hearing loss from noise pollution Detoxifies many well-known carcinomas Infectious disease and immunology Anti-viral (AIDS, hepatitis, herpes, common cold, etc.) Bacterial Infection Certain autoimmune dysfunction Chronic fatigue syndrome Immunosuppression Cancer Cancer prevention Suppress tumor growth Eliminate Carcinogens, mutagens Retard oxidative damage to DNA Prevent wasting disease Ease side effects of chemo- and radiotherapy Pulmonary Break up mucus (esp

Loose skin risk correlates with amount of weight lost, speed of loss, age, and individual skin elasticity rather than the specific method of weight loss
Many patients find peptide therapy one of their most valuable health investments
Prasad, K